Coadministration of branched-chain amino acids and lipopolysaccharide causes matrix metalloproteinase activation and blood-brain barrier breakdown

Mol Neurobiol. 2014 Oct;50(2):358-67. doi: 10.1007/s12035-013-8618-0. Epub 2014 Jan 5.

Abstract

Maple syrup urine disease (MSUD) is an inborn error of metabolism caused by a severe deficiency in the activity of the branched-chain α-keto acid dehydrogenase complex, leading to accumulation of the branched-chain amino acids (BCAA) leucine, isoleucine, and valine. Infections have a significant role in precipitating acute metabolic decompensation in patients with MSUD; however, the mechanisms underlying the neurotoxicity in this disorder are poorly understood. In this study, we subjected rats to the coadministration of lipopolysaccharide (LPS), which is a major component of gram-negative bacteria cell walls, and high concentrations of BCAA (H-BCAA) to determine their effects on the permeability of the blood-brain barrier (BBB) and on the levels of matrix metalloproteinases (MMP-2 and MMP-9). Our results demonstrated that the coadministration of H-BCAA and LPS causes breakdown of the BBB and increases the levels of MMP-2 and MMP-9 in the hippocampus of these rats. On the other hand, examination of the cerebral cortex of the 10- and 30-day-old rats revealed a significant difference in Evan's Blue content after coadministration of H-BCAA and LPS, as MMP-9 levels only increased in the cerebral cortex of the 10-day-old rats. In conclusion, these results suggest that the inflammatory process associated with high levels of BCAA causes BBB breakdown. Thus, we suggest that BBB breakdown is relevant to the perpetuation of brain inflammation and may be related to the brain dysfunction observed in MSUD patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acids, Branched-Chain / administration & dosage
  • Amino Acids, Branched-Chain / blood
  • Amino Acids, Branched-Chain / pharmacology*
  • Animals
  • Blood-Brain Barrier / drug effects*
  • Blood-Brain Barrier / metabolism
  • Cerebral Cortex / drug effects
  • Cerebral Cortex / metabolism
  • Disease Models, Animal
  • Enzyme Activation
  • Hippocampus / drug effects
  • Inflammation / drug therapy
  • Lipopolysaccharides / administration & dosage
  • Lipopolysaccharides / pharmacology*
  • Male
  • Maple Syrup Urine Disease / drug therapy*
  • Maple Syrup Urine Disease / metabolism
  • Maple Syrup Urine Disease / pathology
  • Matrix Metalloproteinases / metabolism*
  • Rats, Wistar

Substances

  • Amino Acids, Branched-Chain
  • Lipopolysaccharides
  • Matrix Metalloproteinases